hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06369285 id: PUMA-ALI-1201 id: 2024-511497-79-00 type: CTIS briefTitle: A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer acronym: ALISCA-Breast1 overallStatus: NOT_YET_RECRUITING date: 2024-12-31 date: 2027-06-30 date: 2028-12-31 date: 2024-04-16 date: 2024-04-16 name: Puma Biotechnology, Inc. class: INDUSTRY briefSummary: PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progression on or after at least two prior lines of endocrine therapy in the recurrent or metastatic setting. This study is intended to evaluate the optimal alisertib dose administered in combination with the selected endocrine therapy. The study is also planned to evaluate the efficacy, safety, and pharmacokinetics of alisertib in combination with endocrine and to identify the biomarker-defined subgroup(s) that may benefit most from combined alisertib and endocrine therapy. conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer conditions: Metastatic Breast Cancer conditions: Recurrent Breast Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 150 type: ESTIMATED name: Alisertib name: Endocrine therapy measure: Objective Response Rate (ORR) Within Dose Subgroup measure: Duration of Response (DOR) Within Dose Subgroup measure: Disease Control Rate (DCR) Within Dose Subgroup measure: Progression Free Survival (PFS) Within Dose Subgroup measure: Overall Survival (OS) Within Dose Subgroup measure: Percentage of Participants With Treatment-Emergent Adverse Events (Adverse Events and Serious Adverse Events) in the Enrolled Population measure: Objective Response Rate (ORR) Within Biomarker-Defined Subgroup measure: Duration of Response (DOR) Within Biomarker-Defined Subgroup measure: Disease Control Rate (DCR) Within Biomarker-Defined Subgroup measure: Progression Free Survival (PFS) Within Biomarker-Defined Subgroup measure: Overall Survival (OS) Within Biomarker-Defined Subgroup sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic city: Rochester state: Minnesota zip: 55905 country: United States lat: 44.02163 lon: -92.4699 hasResults: False
nctId: NCT06369272 id: mRNA-1273-P919 briefTitle: Study to Assess Maternal and Infant Outcomes Following Exposure to SPIKEVAX During Pregnancy overallStatus: COMPLETED date: 2023-03-01 date: 2023-10-20 date: 2023-10-20 date: 2024-04-16 date: 2024-04-16 name: ModernaTX, Inc. class: INDUSTRY briefSummary: The primary objectives of this study are:
* To assess whether exposure to SPIKEVAX during pregnancy is associated with an increased incidence of stillbirth, preterm birth, and medically attended spontaneous abortion. conditions: Maternal Outcomes conditions: Infant Outcomes conditions: Pregnancy studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 1192 type: ACTUAL measure: Number of MCMs measure: Number of Adverse Neonatal and Infant Outcomes measure: Number of Participants with Hypertensive Disorders measure: Number of Stillbirths, Preterm Births, and Medically Attended Spontaneous Abortions measure: Demographics: Participant Region of Residence measure: Demographics: Age at LMP measure: Demographics: Number of Overweight or Obese Participants measure: Demographics: Duration of Health Plan Enrolment Prior to Pregnancy measure: Demographics: Calendar Date of the Pregnancy Outcome measure: Demographics: Participant Race and Ethnicity measure: Demographics: Participant Socio-economic Status measure: Healthcare Utilization: Number of Office Visits, Emergency Department Visits, and Hospitalizations measure: Healthcare Utilization: Number of Distinct Medications Used sex: FEMALE minimumAge: 13 Years maximumAge: 49 Years stdAges: CHILD stdAges: ADULT facility: Carelon Research city: Newton state: Massachusetts zip: 02458 country: United States lat: 42.33704 lon: -71.20922 hasResults: False
nctId: NCT06369259 id: 2023-0997 id: NCI-2024-03302 type: OTHER domain: NCI-CTRP Clinical Registry briefTitle: Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer overallStatus: NOT_YET_RECRUITING date: 2024-10-31 date: 2026-02-01 date: 2028-02-01 date: 2024-04-16 date: 2024-04-16 name: M.D. Anderson Cancer Center class: OTHER briefSummary: To learn if avutometinib in combination with defactinib and cetuximab can help to control unresectable, anti-EGFR-refractory, advanced colorectal cancer. conditions: Advanced Colorectal Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 33 type: ESTIMATED name: Defactinib name: Cetuximab name: Avutometinib measure: Safety and adverse events (AEs) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: MD Anderson Cancer Center city: Houston state: Texas zip: 77807 country: United States name: Christine Parseghian, MD role: CONTACT name: Christine Parseghian, MD role: PRINCIPAL_INVESTIGATOR lat: 29.76328 lon: -95.36327 hasResults: False
nctId: NCT06369246 id: 2023-0893 id: NCI-2024-03308 type: OTHER domain: NCI-CTRP Clinical Registry briefTitle: PRORAD-5 PROstate RADiation in 5 Fractions: Phase Ib Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer overallStatus: NOT_YET_RECRUITING date: 2024-10-31 date: 2025-09-01 date: 2027-09-01 date: 2024-04-16 date: 2024-04-16 name: M.D. Anderson Cancer Center class: OTHER briefSummary: To look at the safety and effectiveness of stereotactic body radiation therapy (SBRT) in treating advanced or high-risk prostate cancer. conditions: Advanced Prostate Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 70 type: ESTIMATED name: Stereotactic Body Radiation Therapy measure: Safety and adverse events (AEs) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: MD Anderson Cancer Center city: Houston state: Texas zip: 77030 country: United States name: Comron Hassanzadeh, MD role: CONTACT phone: 713-657-9802 email: cjhassanzadeh@mdanderson.org name: Comron Hassanzadeh, MD role: PRINCIPAL_INVESTIGATOR lat: 29.76328 lon: -95.36327 hasResults: False
nctId: NCT06369233 id: LNC-MS-002 briefTitle: Clinical Study to Evaluate the Anti-adhesion Efficacy and Safety of MegaShield®-SP in Comparison With Guardix-SP Plus After Spine Surgery overallStatus: RECRUITING date: 2024-04-01 date: 2025-02-28 date: 2025-02-28 date: 2024-04-16 date: 2024-04-25 name: L&C Bio class: INDUSTRY name: PROMeDis briefSummary: This study is Interventional, Parallel, Double-blinded, Randomized study. Subjects aged 20 to 70 years who had a Lumbar discectomy or laminectomy, MegaShield-SP® and Guardix-SP Plus will be applied. conditions: Herniation, Disc studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: MegaShield®-SP name: Guardix-SP Plus measure: MRI scar score measure: Oswestry Disability Index(ODI) score measure: Visual Analog Scale(VAS) Back & Leg Pain Score sex: ALL minimumAge: 20 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Eunpyeong ST. Mary's Hospital status: RECRUITING city: Seoul zip: 03312 country: Korea, Republic of name: HyungYul Park role: CONTACT phone: 02-2030-4536 email: matrixbest@naver.com name: HyungYul Kim, Professor role: PRINCIPAL_INVESTIGATOR lat: 37.566 lon: 126.9784 facility: Severance Hospital status: RECRUITING city: Seoul zip: 03722 country: Korea, Republic of name: Siyoung Park role: CONTACT phone: 2228-2194 email: drspine90@yuhs.ac name: Siyoung Park, Professor role: PRINCIPAL_INVESTIGATOR lat: 37.566 lon: 126.9784 facility: Gangnam Severance Hospital status: RECRUITING city: Seoul zip: 06273 country: Korea, Republic of name: Jiwon Kwon role: CONTACT phone: 2019-3411 email: KWONJJANNG@yuhs.ac name: Jiwon Kwon, Professor role: PRINCIPAL_INVESTIGATOR lat: 37.566 lon: 126.9784 facility: Bundang Seoul National University Hospital status: RECRUITING city: Seoul zip: 13620 country: Korea, Republic of name: Hojung Kim role: CONTACT phone: 031-787-7202 email: oshjkim@gmail.com name: Hojung Kim, Professor role: PRINCIPAL_INVESTIGATOR lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06369220 id: LIA-STI-542 briefTitle: A Study of the Cobas® Liat CT/NG/MG Test Versus Current Standard Practice for Managing Participants at Increased Risk of Sexually Transmitted Infections overallStatus: NOT_YET_RECRUITING date: 2024-06-15 date: 2024-10-31 date: 2024-10-31 date: 2024-04-16 date: 2024-04-16 name: Hoffmann-La Roche class: INDUSTRY name: Roche Molecular Systems, Inc briefSummary: This study is designed to assess the comparative clinical utility of the point of care cobas® liat CT/NG/MG to current standard practices in the diagnosis and treatment of urogenital infections with Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Mycoplasma genitalium (MG). conditions: Chlamydia Trachomatis Infection conditions: Neisseria Gonorrhoeae Infection conditions: Mycoplasma Genitalium Infection studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: DIAGNOSTIC masking: NONE count: 348 type: ESTIMATED name: cobas® liat CT/NG/MG nucleic acid test name: Standard of Care (SOC): Clinician's Standard Practice measure: Percentage of Participants Given Inappropriate Treatments for All Pathogens Combined (CT, NG, and MG) measure: Percentage of Participants Given Inappropriate Treatment for CT Infection measure: Percentage of Participants Given Inappropriate Treatment for NG Infection measure: Percentage of Participants Given Inappropriate Treatment for MG Infection measure: Mean Satisfaction and Confidence Rating Scores of SOC and POC, According to Healthcare Professionals' Responses to the CSDT Questionnaire measure: Mean Satisfaction Rating Scores of SOC and POC, According to Participants' Responses to the PSDT Questionnaire sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06369207 id: 113454 briefTitle: Investigation of the Transmission Pathways of Reflux in Patients With Chronic Venous Evaluation of Reflux Transmission Pathways in Chronic Venous Insufficiency Patients Secondary to Saphenofemoral Reflux overallStatus: ACTIVE_NOT_RECRUITING date: 2023-09-12 date: 2024-02-15 date: 2024-09 date: 2024-04-16 date: 2024-04-22 name: Golestan University of Medical sciences class: OTHER briefSummary: Chronic venous insufficiency (CVI) is one of the most common medical problems in adults that occurs secondary to the reflux of blood through incompetent valves of lower extremity veins. The most common involved valve is the valve located at the saphenofemoral junction. Although the pathway of reflux transmission is not the same in all patients, the removal or ablation of the greater saphenous vein (GSV) is considered a standard treatment in these patients. However, in patients whose reflux is transmitted to branches other than GSV, this treatment leads to the unnecessary destruction of a competent segment of GSV in addition to remaining at least some segments of incompetent veins. So, in this study, the investigators intend to investigate the different pathways of reflux transmission in chronic venous insufficiency patients who are candidates for GSV ablation/stripping because of saphenofemoral junction insufficiency. This cross-sectional study will be conducted with a descriptive-analytical approach. . conditions: Venous Insufficiency studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 50 type: ACTUAL measure: Determination of reflux transmission pathways in CVI patients with SFJ incompetency measure: Anatomic variations of GSV in CVI patients with SFJ incompetency measure: Prevalence of reflux along GSV main trunk in CVI patients with SFJ incompetency measure: Prevalence of reflux along accessory saphenous veins in CVI patients with SFJ incompetency sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Pezhman Kharazm, MD city: Gorgan state: Golestan zip: 4917956808 country: Iran, Islamic Republic of lat: 36.8427 lon: 54.44391 hasResults: False
nctId: NCT06369194 id: POWER5 briefTitle: POWER AUDIT, Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol overallStatus: ACTIVE_NOT_RECRUITING date: 2023-11-14 date: 2024-04-15 date: 2024-04-15 date: 2024-04-16 date: 2024-04-19 name: Grupo Español de Rehabilitación Multimodal class: OTHER briefSummary: The main objective of this study is to analyze the impact on five years survival of an enhanced recovery program (PRI) after radical surgery for colorectal cancer. As secondaries objectives, we propose to analyze comparing survival distributions between patient groups (ERAS/no ERAS) and the relationship between the ERAS program and early incorporation into oncology therapies (RIOT).
nctId: NCT06369181 id: NET 2020 briefTitle: Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC overallStatus: RECRUITING date: 2021-01-01 date: 2027-12-31 date: 2028-12-31 date: 2024-04-16 date: 2024-04-23 name: Fudan University class: OTHER briefSummary: Histology transformation from non-small cell lung cancer (NSCLC) to neuroendocrine carcinomas (NEC), especially from epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma (LADC) to small cell lung cancer (SCLC), is widely recognized as a rare mechanism for NSCLC to confer tyrosine kinase inhibitors (TKIs) resistance. The probability of its occurrence is about 3-14% in NSCLC patients who are resistant to TKI treatment. In addition to EGFR mutations, NSCLC patients carrying ALK/ROS1 mutations and receiving corresponding TKI treatment may also experience NEC transformation(NET).
In a previous study \[Pubmed ID: 35609408\], the investigators demonstrated that NET also develops in NSCLCs without TKI targets or treatments. This phenomenon could be under-recognized, because re-biopsy was less frequently performed in these patients. The investigators had also shown that p53/Rb inactivation might correlated with NET and should be considered for NET risk prediction. In another retrospective studies, it was found that NSCLC patients with RB1/TP53 dual inactivation mutations had a significantly higher probability of NEC pathological transformation than those without RB1/TP53 inactivation mutations (43 times higher than those without mutations). Therefore, the subgroup of NSCLC patients with tumor suppressor gene RB1/TP53 dual inactivation might have elevated risk for NET.
In this study, the investigators proposed to prospectively follow up NSCLC patients with dual RB1/TP53 inactivation (approximately 5% of the total NSCLC). Through prospective and systematic collection of baseline pathological information, clinical treatment process, and imaging data, and as much as possible, repeat pathological biopsies will be performed during disease progression. conditions: Neuroendocrine Carcinoma conditions: Non-small Cell Lung Cancer conditions: Histology Transformation studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 50 type: ESTIMATED measure: neuroendocrine transformation rate sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fudan University Shanghai Cancer Center status: RECRUITING city: Shanghai state: Shanghai zip: 200032 country: China name: Zhengfei Zhu, MD role: CONTACT phone: +86 18017312901 email: fuscczzf@163.com lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06369168 id: Kliniken Essen-Mitte briefTitle: Auricular Acupuncture and Hot Flashes During Adjuvant Endocrine Therapy acronym: OhrHit overallStatus: NOT_YET_RECRUITING date: 2024-05-20 date: 2024-11-20 date: 2025-11-20 date: 2024-04-16 date: 2024-04-23 name: Kliniken Essen-Mitte class: OTHER name: Karl and Veronica Carstens Foundation briefSummary: With this clinical trial we investigate whether auricular acupuncture during adjuvant endocrine therapy has an improving effect on hot flashes, which are often perceived as psychologically and physically stressful in self-assessment of women with breast cancer.
Empirical studies indicate that body acupuncture has positive effects on hot flashes. As auricular acupuncture offers a number of advantages over body acupuncture, a three-armed randomised controlled research design is being used to investigate whether hot flashes caused by endocrine therapy are also reduced by ear acupuncture. Balanced ear acupuncture will be compared with NADA ear acupuncture in terms of efficacy and effectiveness. In addition, the effects of the two forms of therapy on the patients' individual quality of life, fatigue, stress perception and sleep quality will be analysed. conditions: Hot Flashes studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: randomized controlled trial primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 99 type: ESTIMATED name: auricular acupuncture measure: subscale somato-vegetative symptoms of the Menopause Rating Scale (MRS) measure: Menopause Rating Scale (MRS) total score measure: Psychological symptoms and urogenital symptoms subscales of the MRS measure: functional assessment of cancer therapy - breast (FACT-B) measure: perceived stress questionnaire (PSQ) measure: insomnia severity index (ISI) measure: big five inventory (BFI) measure: Expected effect of the respective intervention on a 100mm visual analogue scale measure: intensity and degree of impairment due to hot flashes on a 100mm visual analogue scale measure: adverse events (AEs) sex: FEMALE minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06369155 id: 24-061 briefTitle: Azenosertib in Uterine Serous Carcinoma: Biomarker Study overallStatus: NOT_YET_RECRUITING date: 2024-09 date: 2026-01-31 date: 2027-01-31 date: 2024-04-16 date: 2024-04-16 name: Joyce Liu, MD class: OTHER name: National Cancer Institute (NCI) name: Zentalis briefSummary: This research study is being done to investigate how Azenosertib affects tumor cells of persistent or recurrent uterine serous carcinoma.
-Azenosertib (a type of Wee1 inhibitor) conditions: Uterine Serous Carcinoma conditions: Uterine Carcinoma conditions: Uterine Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 25 type: ESTIMATED name: Azenosertib measure: Percentage Change in Replication Fork Speed in Overall Response measure: Percentage Change in Replication Fork Speed in 6 Month Progression Free Survival (PFS6) measure: Overall Response Rate (ORR) measure: 6-month Progression-Free Survival (PFS6) measure: Clinical Benefit Rate (CBR) measure: Median Duration of Overall Response (DOR) measure: Median Progression-Free Survival (PFS) measure: Grade 3-5 Treatment-related Toxicity Rate sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Brigham and Women's Hospital city: Boston state: Massachusetts zip: 02215 country: United States name: Joyce Liu, MD, MPH role: CONTACT phone: 617-632-5269 email: joyce_liu@dfci.harvard.edu name: Joyce Liu, MD, MPH role: PRINCIPAL_INVESTIGATOR lat: 42.35843 lon: -71.05977 facility: Dana-Farber Cancer Institute city: Boston state: Massachusetts zip: 02215 country: United States name: Joyce Liu, MD, MPH role: CONTACT phone: 617-632-5269 email: joyce_liu@dfci.harvard.edu name: Joyce Liu, MD, MPH role: PRINCIPAL_INVESTIGATOR lat: 42.35843 lon: -71.05977 hasResults: False
nctId: NCT06369142 id: GE IDE No. L00123 briefTitle: Intracoronary Stenting and Additional Results Achieved by ShockWAVE Coronary Lithotripsy acronym: ISAR-WAVE overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2027-04-30 date: 2027-07-31 date: 2024-04-16 date: 2024-04-16 name: Deutsches Herzzentrum Muenchen class: OTHER name: Gemeinsamer Bundesaussschuss name: EvidentIQ Germany GmbH name: Monitoring Services GmbH name: Institute of AI and Informatics in Medicine Technical University of Munich briefSummary: The clinical trial is intended to evaluate the efficacy, safety and economic benefit of coronary lithotripsy compared to other additional procedures (cutting or super high pressure balloon angioplasty, ablative procedures) in lesion preparation and interventional treatment of severely calcified coronary stenoses. conditions: Coronary Artery Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: The study participant as well as the follow-up physicians and site personal are blinded. whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 666 type: ESTIMATED name: Intravascular lithotripsy (IVL) name: Standard non-IVL methods measure: Combined endpoint of major cardiac and cerebrovascular events measure: Mortality measure: Cardiac mortality measure: Non-fatal myocardial infarction measure: Non-fatal stroke measure: Clinically indicated target vessel revascularization measure: Definite stent thrombosis measure: Clinically indicated non-target vessel revascularization measure: Hospitalization due to acute coronary syndrome measure: Symptoms of coronary heart disease (CHD): physical health status measure: Symptoms of CHD: mental health status measure: Bleeding during index hospitalization or ≤30 days (BARC 3-5) measure: Procedural failure (failed application of study-related additional procedure, final TIMI flow <3, >30% residual stenosis, vessel perforation, stent loss, stent delivery failure) measure: Medical costs (index hospitalization and costs for re-hospitalization due to acute coronary syndrome) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Deutsches Herzzentrum München city: Munich state: Bavaria zip: 80636 country: Germany name: Salvatore Cassese, MD, PHD role: CONTACT phone: 0049891218 phoneExt: 2764 email: cassese@dhm.mhn.de name: Salvatore Cassese, MD, PDH role: PRINCIPAL_INVESTIGATOR lat: 48.13743 lon: 11.57549 hasResults: False
nctId: NCT06369129 id: CEBD-CU-2024-06-16 briefTitle: Accuracy& Orbital Volume Using Patient Specific Titanium Implant Vs Zirconia for Orbital Floor Reconstruction overallStatus: RECRUITING date: 2024-04-06 date: 2025-08 date: 2025-08 date: 2024-04-16 date: 2024-04-17 name: Cairo University class: OTHER briefSummary: Comparative study used to assess if the patient specific zirconia implant will provide better accuracy, intraoperative adaptability, precise orbital volume and soft tissue reaction with more cost effectiveness than the patient specific titanium implants in orbital floor reconstruction after blow out fractures . conditions: Blow-Out Fractures conditions: Orbital Fractures conditions: Orbital Floor Fracture conditions: Orbital Trauma studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A randomized clinical trial.
* Positive controlled : Both groups receiving treatment. primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Orbital floor reconstruction with Patient Specific Zirconia Implant name: Orbital floor reconstruction with Patient Specific Titanium Implant measure: Orbital Volume measure: Accuracy of the patient specific implant in the orbital floor reconstruction measure: Cost effectiveness measure: Patient satisfaction sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Cairo University status: RECRUITING city: Cairo zip: 11511 country: Egypt name: OLA A. ELMORSY, PHD role: CONTACT phone: 00201141234877 email: dr.ola.elmorsy@gmail.com lat: 30.06263 lon: 31.24967 hasResults: False